Scholarlink

<p>Due to the rapidly increasing worldwide problem of microbial resistance, particularly due to nonindicated antibiotic use and livestock fattening, most newly approved antibiotics have the status of limited-access antibiotics. These are primarily combinations of cephalosporin and beta-lactamase inhibitor (BLI) for use against multidrug-resistant, Gram-negative pathogens and “problem germs” that are difficult to treat due to their normal genetic make-up, such as <i>Stenotrophomonas maltophilia</i> or <i>Acinetobacter baumanii</i>. Monoclonal antibodies, e.g., against respiratory syncytial virus (RSV) and specific bacteriophages, provide additional strategies. Further innovative substances are in the developmental pipeline. Nevertheless, the most important measure remains prevention, including through consistent basic hygiene and vaccinations as well as through responsible policy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue Antiinfektiva

  • 期刊论文

  • 发表日期：

    2025年9月29日

查看全文
  • Uta Kunter

摘要

Due to the rapidly increasing worldwide problem of microbial resistance, particularly due to nonindicated antibiotic use and livestock fattening, most newly approved antibiotics have the status of limited-access antibiotics. These are primarily combinations of cephalosporin and beta-lactamase inhibitor (BLI) for use against multidrug-resistant, Gram-negative pathogens and “problem germs” that are difficult to treat due to their normal genetic make-up, such as Stenotrophomonas maltophilia or Acinetobacter baumanii. Monoclonal antibodies, e.g., against respiratory syncytial virus (RSV) and specific bacteriophages, provide additional strategies. Further innovative substances are in the developmental pipeline. Nevertheless, the most important measure remains prevention, including through consistent basic hygiene and vaccinations as well as through responsible policy.